Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Nektar Therapeutics (NASDAQ:NKTR) Thursday, maintaining a Buy rating on the stock with …
Nektar Therapeutics (NASDAQ:NKTR) and The University of Texas MD Anderson Cancer Center announced a research collaboration that includes a Phase 1/2 clinical study …
Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan’s Ministry …
Nektar Therapeutics (NASDAQ:NKTR) announced today that it has received a $100 million payment under a license agreement with AstraZeneca. The cash payment under the Nektar-AstraZeneca …
Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca announced that MOVANTIK™ (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) …
Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on Nektar Therapeutics (NASDAQ:NKTR), following the news that AstraZeneca plc (ADR) (NYSE:AZN) will commercialize Movantik in the US jointly …
By Sarah Roden It’s been a busy week in the pharmaceutical industry with new data emerging on trial drugs and M&A between drug …
Brean Capital analyst Jonathan Aschoff came out today with a research note on Nektar Therapeutics (NASDAQ:NKTR), reducing the price target to $17 (from $20) and …
Piper Jaffray analyst Joshua Schimmer came out with a research note on Nektar Therapeutics (NASDAQ:NKTR), following the company’s fourth-quarter results posting revenue of $19.5 million compared to Jaffray’s estimate …
Brean Capital analyst Jonathan Aschoff was out pounding the table on Nektar Therapeutics (NASDAQ:NKTR) Wednesday, reiterating a Buy rating and a price target …
